QNTM
Income statement / Annual
Last year (2025), Quantum BioPharma Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Quantum BioPharma Ltd.'s net income was -$26.63 M.
See Quantum BioPharma Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
08/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$20.63 K |
$0.00 |
| Cost of Revenue |
$555.33 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.04 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$555.33 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.84 M
|
$0.00
|
$20.63 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
| Research and Development Expenses |
$2.81 M
|
$6.08 M
|
$3.86 M
|
$6.91 M
|
$6.33 M
|
$7.83 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$9.31 M
|
$13.20 M
|
$15.98 M
|
$23.37 M
|
$18.11 M
|
$20.49 M
|
$17.49 M
|
$2.82 M
|
$29.63 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.22 M
|
$9.31 M
|
$13.20 M
|
$15.98 M
|
$23.37 M
|
$18.11 M
|
$20.49 M
|
$17.49 M
|
$2.82 M
|
$29.63 K
|
| Other Expenses |
$0.00
|
$742.80 K
|
$6.73 M
|
$4.54 M
|
$4.05 M
|
$4.75 M
|
-$45.53 K
|
$1.13 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$15.03 M
|
$16.14 M
|
$23.79 M
|
$27.43 M
|
$33.74 M
|
$30.69 M
|
$20.44 M
|
$18.62 M
|
$2.82 M
|
$29.63 K
|
| Cost And Expenses |
$15.59 M
|
$16.14 M
|
$23.79 M
|
$27.43 M
|
$33.74 M
|
$30.69 M
|
$22.48 M
|
$18.62 M
|
$2.82 M
|
$29.63 K
|
| Interest Income |
$240.22 K
|
$572.89 K
|
$786.36 K
|
$367.74 K
|
$1.29 K
|
$3.69 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$629.47 K
|
$47.58 K
|
$299.00
|
$48.82 K
|
$69.40 K
|
$235.58 K
|
$155.32 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$555.33 K
|
$490.57 K
|
$2.51 M
|
$4.54 M
|
$4.05 M
|
$3.90 M
|
$1.94 M
|
$134.50 K
|
$0.00
|
$0.00
|
| EBITDA |
-$15.03 M |
-$14.38 M |
-$15.72 M |
-$22.12 M |
-$29.82 M |
-$24.32 M |
-$31.98 M |
-$16.54 M |
-$2.80 M |
-$29.63 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-135.86
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-135.86
|
0
|
| Total Other Income/Expenses Net |
-$11.84 M
|
$1.22 M
|
$5.56 M
|
$725.95 K
|
-$194.30 K
|
$2.24 M
|
-$11.60 M
|
-$16.67 M
|
$0.00
|
-$29.63 K
|
| Income Before Tax |
-$27.43 M
|
-$14.92 M
|
-$18.23 M
|
-$26.70 M
|
-$33.94 M
|
-$28.45 M
|
-$34.08 M
|
-$16.67 M
|
-$2.80 M
|
-$29.63 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-135.86
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$26.63 M
|
-$14.20 M
|
-$17.90 M
|
-$23.61 M
|
-$35.29 M
|
-$31.80 M
|
-$39.13 M
|
-$16.67 M
|
-$2.80 M
|
-$29.63 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-135.86
|
0
|
| EPS |
-8.11 |
-12.49 |
-29.39 |
-39.62 |
-65.63 |
-171.62 |
-360.45 |
-183.54 |
-27.75 |
-0.29 |
| EPS Diluted |
-8.11 |
-12.49 |
-29.39 |
-39.62 |
-65.63 |
-171.62 |
-360.45 |
-183.54 |
-27.75 |
-0.29 |
| Weighted Average Shares Out |
$3.29 M
|
$1.14 M
|
$609.06 K
|
$595.88 K
|
$537.62 K
|
$185.29 K
|
$108.56 K
|
$90.85 K
|
$101.00 K
|
$101.00 K
|
| Weighted Average Shares Out Diluted |
$3.29 M
|
$1.14 M
|
$609.06 K
|
$595.88 K
|
$537.62 K
|
$185.29 K
|
$108.56 K
|
$90.85 K
|
$101.00 K
|
$101.00 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
